The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer

International Journal of Gastrointestinal Cancer

Volumn 32, Issue 1, 2002, Pages 1-6

  Morse, Michael A ^a   Nair, Smita K ^a   Boczkowski, David ^a   Tyler, Douglas ^a   Hurwitz, Herbert I ^a   Proia, Alan ^a   Clay, Timothy M ^a   Schlom, Jeffrey ^b   Gilboa, Eli ^a   Lyerly, H Kim ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

CEA; Dendritic cells; Immunotherapy; mRNA; Pancreatic cancer

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TUMOR VACCINE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; AUTOIMMUNE DISEASE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CASE REPORT; DENDRITIC CELL; HIGH RISK PATIENT; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOREACTIVITY; IMMUNOTHERAPY; MESSENGER RNA SYNTHESIS; MINIMAL RESIDUAL DISEASE; PANCREAS CANCER; PANCREAS RESECTION; PRIORITY JOURNAL; REVIEW; SAFETY; TUMOR IMMUNITY;

EID: 0344837817     PISSN: 01694197     EISSN: None     Source Type: Journal    
DOI: 10.1385/ijgc:32:1:1     Document Type: Review

References (13)

1. Ghaneh P, Slavin J, Sutton R, Hartley M, Neoptolemos JP. Adjuvant therapy in pancreatic cancer. World J Gastroenterol 2001;7:482-489.
2. Ahmad NA, Lewis JD, Ginsberg GG, Haller DG, Morris JB, Williams NN, et al. Long term survival after pancreatic resection for pancreatic adenocarcinoma. Am J Gastroenterol 2001;96:2609-2615.
3. Lieberman SM, Horig H, Kaufman HL. Innovative treatments for pancreatic cancer. Surg Clin North Am 2001;81:715-739.
4. Gjertsen MK, Buanes T, Rosseland AR, Bakka A, Gladhaug I, Soreide O, et al. Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: clinical and immunological responses in patients with pancreatic adenocarcinoma. Int J Cancer 2001;92:441-450.
5. Staib L, Birebent B, Somasundaram R, Purev E, Braumuller H, Leeser C, et al. Immunogenicity of recombinant GA733-2E antigen (CO17-1A, EGP, KS 1-4, KSA, Ep-CAM) in gastro-intestinal carcinoma patients. Int J Cancer 2001;92:79-87.
6. Jaffee EM, Hruban RH, Biedrzycki B, Laheru D, Schepers K, Sauter PR, et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 2001;19:145-156.
7. Nestle FO, Banchereau J, Hart D. Dendritic cells: on the move from bench to bedside. Nat Med 2001;7:761-765.
8. Piemonti L, Monti P, Zerbi A, Balzano G, Allavena P, Di Carlo V. Generation and functional characterisation of dendritic cells from patients with pancreatic carcinoma with special regard to clinical applicability. Cancer Immunol Immunother 2000;49:544-550.
9. Nair SK, Hull S, Coleman D, Gilboa E, Lyerly HK, Morse MA. Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA. Int J Cancer 1999;82:121-124.
10. Morse MA, Deng Y, Hull S, Coleman D, Nair S, Schlom J, et al. A phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res 1999;5:1331-1338.
11. Zamora C, Sahel J, Cantu DG, Heyries L, Bernard JP, Bastid C, et al. Intraductal papillary or mucinous tumors (IPMT) of the pancreas: report of a case series and review of the literature. Am J Gastroenterol 2001;96:1441-1447.
12. White RR, Hurwitz HI, Morse MA, Lee C, Anscher MS, Paulson EK, et al. Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. Ann Surg Oncol 2001;8:758-765.
13. Coulie PG, Karanikas V, Colau D, Lurquin C, Landry C, Marchand M, et al. A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc Natl Acad Sci USA 2001;98:10290-10295.